The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-On Therapy to Metformin in Patients With Uncontrolled Type 2 Diabetes Mellitus

Diabetes Therapy - United States
doi 10.1007/s13300-016-0206-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Cost-Effectiveness Analysis of Linagliptin Versus Sulfonylurea as Add-On Treatment to Metformin for the Treatment of Diabetes Mellitus Type 2 Patients in Indonesia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Dapagliflozin: Cost-Effectiveness as an Add-On Therapy to Metformin in the Treatment of Type 2 Diabetes (T2DM) in Argentina and Chile

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Cost-Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors as an Add-On to Metformin in the Treatment of Type 2 Diabetes Mellitus From a UK Healthcare System Perspective

BMC Health Services Research
Health Policy
2015English

The Cost-Effectiveness of Dulaglutide Versus Liraglutide in Patients With Type 2 Diabetes Mellitus in Taiwan

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Cost-Utility Analysis of Liraglutide Compared With Sulphonylurea or Sitagliptin, All as Add-On to Metformin Monotherapy in Type 2 Diabetes Mellitus

Diabetic Medicine
Internal MedicineEndocrinologyMetabolismDiabetes
2012English

Comparison of Antioxidative Effect of Metformin and Combination of Metformin-Sulfonylurea in Type 2 Diabetes Mellitus Patients

Journal of Young Pharmacists
ToxicologyPharmaceuticsPharmacology
2017English

A Randomized, Open Label, Comparative Study of Biotin as an Add-On Therapy to Metformin vs Metformin Alone in Newly Diagnosed Type 2 Diabetes Mellitus Patients

IOSR Journal of Dental and Medical Sciences
2016English

Pdb137 - Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients With Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Effectiveness Analysis of Exenatide Twice Daily (BID) Versus Insulin Glargine Once Daily (QD) as Add-On Therapy in Chinese Patients With Type 2 Diabetes Mellitus Inadequately Controlled by Oral Therapies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy